Over the past two decades, ribavirin has been an integral component of treatment for hepatitis C virus (HCV) infection, where it has been shown to improve the efficacy of (pegylated) interferon. However, because of treatment-limiting side effects and its additive toxicity with interferon, the search for interferon-and ribavirin-free regimens has been underway. The recent approvals of all-oral direct acting antivirals (DAAs) have revolutionized the HCV therapeutic landscape, and initially it was expected that the role of ribavirin with DAA regimens would be eliminated. On the contrary, what we have witnessed is that ribavirin retains an important role in the optimal treatment of some subgroups of patients, particularly those that historically have been considered the most difficult to cure. Fortunately, it has also been recognized that the safety profile of ribavirin is improved when co-administered with all-oral DAA combinations in the absence of interferon. Despite the antiviral mechanism of action of ribavirin being poorly understood, we now have a range of novel insights into the potential role of ribavirin in all-oral DAA HCV treatment and greater insight into the antiviral mechanism by which it continues to provide clinical benefit for defined patient groups.
with interferon or peginterferon results in higher rates of some AEs, compared with either agent alone (Fig. 1A, B) . 1, 2 Finally, because of a teratogenic effect in animals, 12 ribavirin is contraindicated during pregnancy, warranting a Category X designation, and contraception is required in all women of child-bearing potential, including those with male partners taking the medication. 13, 14 Ribavirin is not metabolized via a cytochrome P450-mediated mechanism and, therefore, has a low potential for drug-drug interactions. 13 However, there are issues with a small number of agents with additive toxicity, e.g. the nucleoside reverse transcriptase inhibitors zidovudine and didanosine as well as the immunosuppressant drug azathioprine. No issues have been identified with ribavirin and any approved direct-acting antiviral (DAA) therapies for HCV.
| THE ROLE OF RIBAVIRIN IN THE INTERFERON-FREE ERA
In the interferon-free era of HCV treatment, most clinical trials have been designed to systematically evaluate DAA regimens with or without ribavirin. Ribavirin's role was expected to diminish or even be eliminated over time, but pivotal trial data indicate that, for certain regimens, it remains an important component for the optimal treatment of some patients. Deciding whether to include ribavirin as a therapy component, and how best to manage its use, largely depends on HCV genotype (GT), GT subtype, fibrosis stage, and the treatment regimen itself (Table 1) .
| Optimizing therapy by maximizing SVR rates in HCV GT1-infected patients
Clinical trial data for interferon-free DAA combinations have shown that adding ribavirin results in higher SVR rates in select GT1-infected patients. However, it should be recognized that, even without ribavirin, highly potent DAA combinations that target multiple components of the HCV lifecycle have a high barrier to resistance and achieve nearly universal on-treatment rates of undetectable HCV ribonucleic acid (RNA). Therefore, in most cases, adding ribavirin maximizes SVR rates by reducing post-treatment viral relapse, presumably through action within hepatocytes.
Sofosbuvir, a nucleotide analogue NS5B inhibitor, has been evaluated in combination with the NS5A inhibitor ledipasvir with and without ribavirin in patients with GT1 infection in the phase 3 trials, ION-1, ION-2 and ION-3. [15] [16] [17] Among treatment-naive patients recruited in ION-1 (N=865) and ION-3 (N=647), SVR rates in all treatment arms were high and adding ribavirin did not appear to confer additional benefit over that observed with ledipasvir/sofosbuvir. 15, 17 However, among treatment-experienced patients recruited in ION-2 (N=440), the addition of ribavirin was shown to increase SVR rates compared with ledipasvir/sofosbuvir in certain patient subsets. 16 For example, . 16 However, it is difficult to draw conclusions from study samples that were not powered to detect differences within subpopulations, and may explain why the approval for 12-week treatment with ledipasvir/sofosbuvir in treatment-experienced patients without cirrhosis does not include the use of ribavirin for either GT1 subtype. 18, 19 Conversely, the lack of benefit with ribavirin seemed clear in GT1-infected treatment-experienced cirrhotic patients treated for 24 weeks. Treatment with ledipasvir/sofosbuvir with or without ribavirin for 24 weeks achieved SVR rates of 100% (n=22 in each), while treatment for 12 weeks with or without ribavirin achieved SVR rates of 82% and 86% respectively (n=22 in each).
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This led to what seemed like the incontrovertible recommendation that 24-week ledipasvir/sofosbuvir treatment in patients with compensated cirrhosis be administered without ribavirin. 18, 19 However, in the SIRIUS study (N=155) of GT1-infected patients with cirrhosis who had failed therapy with peginterferon/ribavirin and a protease inhib- Key points
• Ribavirin has been an integral component of treatment for hepatitis C virus (HCV) infection for the past two decades.
• In the interferon-free era of HCV treatment, ribavirin has retained an important role in the optimal treatment of some difficult-to-cure subgroups of patients.
• The safety profile of ribavirin is improved when co-administered with all-oral direct-acting antiviral (DAA) combinations in the absence of interferon.
• Recently, new insights have been gained into the antiviral mechanism by which ribavirin delays or prevents the emergence of resistance-associated substitutions (RASs).
T T A B L E 1 (continued) rates of relapse. 25 The impact on the rate of SVR12 was predominantly observed in HCV GT1a-infected treatment-experienced cirrhotic patients with baseline NS5A RASs that conferred >100-fold shift in EC 50 . Conversely, in patients without detectable NS5A RASs at baseline, SVR rates were unaffected by treatment extension or addition of ribavirin. 25 These data suggest that ribavirin may improve DAA efficacy in patients infected with a detectable proportion of resistant HCV, but the mechanism of this effect remains poorly understood.
The possible benefit of ribavirin addition in patients with GT1a
infection has also been demonstrated in those receiving the approved combination of ombitasvir (an NS5A inhibitor), paritaprevir (an NS3/4A protease inhibitor, pharmacokinetically enhanced by ritonavir co-administration) and dasabuvir (a non-nucleoside NS5B inhibitor). In the randomized, placebo-controlled SAPPHIRE trials, overall SVR rates of 96% were demonstrated in GT1a treatment-naive and -experienced patients without cirrhosis who received 12 weeks of ombitasvir/paritaprevir/ritonavir plus dasabuvir and ribavirin. [26] [27] [28] [29] Subsequently, a set of randomized, regimen-controlled trials examined the efficacy and safety of this 12-week regimen with and without ribavirin in treatment-naive patients without cirrhosis, infected with either HCV GT1a (PEARL-IV) 30 or HCV GT1b (PEARL-III), 30 or treatmentexperienced, GT1b-infected patients (PEARL-II). 31 These trials showed that ribavirin confers a possible benefit in treatment-naive, GT1a-infected patients without cirrhosis, in whom it numerically increased SVR rates from 90% to 97%. 30 In contrast, in GT1b-infected patients without cirrhosis, 100% (300/300) SVR rates were achieved without ribavirin, even among those with a null response to prior peginterferon plus ribavirin therapy. [28] [29] [30] [31] In the TURQUOISE-II study (N=380), which enrolled HCV GT1-infected, treatment-naive and -experienced patients with cirrhosis, SVR12 rates were high in both GT1b-(99.2%
[118/119]) and GT1a-infected (91.6% [239/261]) individuals treated with ombitasvir/paritaprevir/ritonavir plus dasabuvir and ribavirin for 12 or 24 weeks. 28, 29, 32 The longer therapy duration improved the SVR rate in GT1a-infected patients with a prior null response to peginterferon plus ribavirin, but conferred no additional benefit in the rest of the patient population. The high response in HCV GT1b patients with ribavirin led to the TURQUOISE-III study, a single-arm (N=60) trial, to evaluate whether HCV GT1b-infected patients with cirrhosis could be effectively treated with the 12-week ribavirin-free ombitasvir/paritaprevir/ritonavir plus dasabuvir regimen. All 60 patients achieved SVR12; however, because of the small number of patients enrolled into the study, 95% confidence intervals were 94%-100%. Collectively, these data for ombitasvir/paritaprevir/ritonavir plus dasabuvir show that adding ribavirin is useful for HCV GT1a but does not confer additional benefit in HCV GT1b-infected patients, even those with compensated cirrhosis.
These examples demonstrate that, with multiple DAA regimens, ribavirin may maximize SVR rates through reducing relapse rates in select HCV GT1-infected patients, particularly those with GT1a, in which a lower barrier to resistance has been demonstrated with the protease, NS5A, and non-nucleotide polymerase inhibitor classes compared. In combination with GT1b agents with a higher barrier to resistance, particularly nucleotide polymerase inhibitors, the ribavirin effect is less clear.
However, small studies may be misleading. Ribavirin did not appear to affect the SVR12 rates in the COSMOS trial (N=167), which randomized HCV GT1-infected, treatment-naive or -experienced patients to receive sofosbuvir and the NS3/4A protease inhibitor simeprevir, with and without ribavirin, for 12 or 24 weeks. 34 The high SVR rates in all groups suggested that ribavirin was of no benefit and that the Q80K substitution, which affects the response of HCV GT1a-infected patients to simeprevir, did not have a major impact in this trial (although four of the six relapsers in this study had this polymorphism). 34 However, the larger phase 3 OPTIMIST-1 35 and OPTIMIST-2 trials 36 showed that, with sofosbuvir and simeprevir, the presence of the Q80K substitution at baseline was associated with lower SVR rates with 12 weeks of therapy in patients with cirrhosis and lower SVR rates when treatment was shortened to 8 weeks in non-cirrhotic patients. Extending therapy to 12 weeks in the non-cirrhotic group overcame the effect of the baseline Q80K polymorphism. Based on the COSMOS results, neither addition of ribavirin nor extended treatment duration to 24 weeks were evaluated in the OPTIMIST trials. 35, 36 Both of these strategies have proven useful to overcome resistance in other studies, and one wonders whether either approach would have improved SVR rates with this regimen.
Recently, pooled analyses of phase 2 and 3 trials of the secondwave NS5A inhibitor, elbasvir, and the second-generation protease inhibitor, grazoprevir, have demonstrated a role for ribavirin in select HCV GT1-infected populations. A pooled analysis of HCV GT1-infected patients with compensated cirrhosis demonstrated that including ribavirin and extending therapy from 12 to 16/18 weeks increased the SVR rate from 92% to 100% in the subset of non-responders to prior peginterferon plus ribavirin therapy (Table 1) . 37 A similar numerical increase in SVR rate was observed when ribavirin was included and therapy was extended from 12 to 16/18 weeks in HCV GT1a-infected patients with on-treatment failure to prior therapy with peginterferon plus ribavirin with or without a first-generation protease inhibitor (90% vs 100%; Table 1 ). infection, baseline RASs had no effect on response rates for 8 weeks of grazoprevir/elbasvir therapy with or without ribavirin (90% vs 94%; Table 1 ). 40 Collectively, these data suggest that ribavirin increases the barrier to resistance, which is particularly relevant for patients with GT1a infection receiving regimens that include DAAs with low barriers to resistance such as NS5A inhibitors, protease inhibitors and non-nucleoside NS5B inhibitors.
| Optimizing therapy by shortening treatment duration in HCV GT1-infected patients
Recent data, particularly in patients with cirrhosis, have shown that adding ribavirin to DAA regimens may allow for shortened treatment durations without reducing SVR rates. As discussed above, a pooled analysis of phase 2 and 3 trials in HCV GT1-infected patients with cirrhosis receiving ledipasvir/sofosbuvir for 12 or 24 weeks showed that ribavirin can boost SVR rates in patients treated for 12 weeks, while ribavirin confers little additional benefit in those treated for 24 weeks, suggesting that ribavirin compensates for reducing the length of treatment. 21 Combined with the results from the SIRIUS study, 20 also discussed above, these data suggest a role for ribavirin in reducing the treatment duration of ledipasvir/sofosbuvir in treatment-experienced patients with cirrhosis. 20, 21 Further insight into ribavirin's potential to shorten DAA treatment duration will come from the multitude of "real-world" studies currently rates from 85% (45/53) to 100% (11/11) . Although these data support the concept that ribavirin may allow shorter treatment duration, the small number of patients and the non-randomized nature of this study limit interpretation of results.
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| Optimizing therapy in other HCV GT1-infected patient populations
In the interferon era, patients with very advanced liver disease were highly challenging to treat because of poor efficacy and increased toxicity. Consequently, there has been an urgent medical need for safer and more effective treatment options. Well-tolerated oral DAA therapies have changed the options for these patients dramatically,
but results from clinical trials of DAA regimens have shown that, in many cases, ribavirin is still of benefit.
| Decompensated liver disease and preliver transplant
Until recently, few data existed for patients with decompensated cir- with compensated cirrhosis. 47 The reasons for this are unclear; however, addition of ribavirin may be important to maximize SVR rates in this patient population. Of note, in ASTRAL-4, a weight-based ribavirin dose of 1000-1200 mg/day was used compared with a lower ribavirin starting dose of 600 mg in the SOLAR and ALLY-1 studies (increased doses as tolerated were used in SOLAR-1 and -2). [42] [43] [44] 46 For patients with detectable HCV at the time of transplant, postoperative recurrence of HCV in the graft is universal 48 and, therefore, HCV-infected patients on liver transplant waiting lists remain a population with high unmet medical need. Limited data are available for patients in the pretransplant setting; however, a small phase 2 study of sofosbuvir plus ribavirin for 12 weeks demonstrated prevention of HCV recurrence in 70% (30/43) of patients with HCV-related liver cancer who achieved an HCV RNA of <25 IU/mL prior to transplant. 49 Although addition of ribavirin is likely beneficial over sofosbuvir monotherapy, whether the use of a second DAA would achieve similar benefits is unknown. Ribavirin was again fairly well tolerated even in these patients with advanced cirrhosis.
| Post-liver transplant
Similar to trials in patients with decompensated liver disease, most studies in post-liver transplant recipients have not been designed to formally evaluate ribavirin's role. In the post-transplant setting, SVR rates of 70% (28/40 patients) have been described with sofosbuvir plus ribavirin. 50 Although these rates seem suboptimal compared to the non-transplant setting, it is important to remember that trials included patients with fibrosing cholestatic hepatitis and recurrent cirrhosis post-transplant. Trials of regimens that combine DAAs and ribavirin have shown higher SVR rates in transplant recipients, including ledipasvir/sofosbuvir plus ribavirin, which yielded SVR rates of 95%-98%
(SOLAR-1 and SOLAR-2), 42, 43 and daclatasvir and sofosbuvir plus ribavirin, which yielded SVR rates of 95% (ALLY-1). 44 To date, all trials of ledipasvir/sofosbuvir, and daclatasvir and sofosbuvir, have included ribavirin. Given concerns about tolerability, ribavirin has been started at a lower dose in the post-transplant setting (typically 600 mg daily) with no obvious clinical consequence; however, higher (or lower doses) have not been evaluated. In part 1 of the CORAL-1 study, an SVR rate of 97% was reported in 34 liver transplant recipients with HCV GT1 who received ombitasvir/paritaprevir/ritonavir and dasabuvir plus ribavirin for 24 weeks. 51 Whether ribavirin plays an important role for HCV GT1-infected liver transplant recipients without cirrhosis has been evaluated in part 2 of the CORAL-I study. 52 In part 2, HCV GT1b-infected patients who were either treatment-naive or prior relapsers to peginterferon/ ribavirin were treated with 24 weeks of ombitasvir/paritaprevir/ritonavir and dasabuvir without ribavirin. All 13 patients achieved SVR, reinforcing the high barrier to resistance in GT1b-infected patients that allows for the exclusion of ribavirin. 52 Patients with GT1a infection and those with GT1b infection who were prior non-responders were treated with 24 weeks of ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin; 26 of 27 (96%) achieved SVR.
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The real-world effectiveness of sofosbuvir-containing regimens in the post-transplant setting, with or without ribavirin, is being evaluated in the observational HCV-TARGET study 53 and the French prospective CUPILT study. 54 To date, an SVR4 rate of 91% (52/57 patients) has been described with simeprevir and sofosbuvir, compared with 82% (9/11 patients) with simeprevir and sofosbuvir plus ribavirin in the HCV-TARGET cohort. 53 In the CUPILT study, treatment with daclatasvir and sofosbuvir for 12 or 24 weeks has yielded SVR12 rates of 97% (73/75) without ribavirin and 95% (52/55) with ribavirin. 54 In both studies, the lack of randomization and the low patient numbers, particularly in the ribavirin-containing groups, limited any conclusions regarding whether there is a role for ribavirin in liver transplant patients as part of this regimen.
| Renal impairment
Currently patients with severe renal impairment have limited treatment options and there remains urgent medical need to evaluate DAA regimens in these patients. Using ribavirin in this setting is problematic because of the renal excretion of ribavirin and its metabolites resulting in an increase in drug exposure and potential toxicities.
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However, a reduced daily dose of 200 mg of ribavirin can be administered to patients with severe renal impairment, including those who are undergoing haemodialysis.
14 The RUBY-I study investigated the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with (HCV GT1a) and without (HCV GT1b) low-dose ribavirin for 12 weeks in patients with severe renal impairment or end-stage renal disease. 56, 57 Results show that 90% (18/20) of patients achieved an SVR. Of the two patients who failed to achieve an SVR, one GT1a-infected patient experienced virological relapse and one patient died after the end of treatment because of reasons not attributed to DAAs or ribavirin. 57 However, in patients with HCV GT1a infection and who received ribavirin, anaemia was responsible for nine out of 13 patients requiring ribavirin dose interruption, and four requiring erythropoietin. 57 No patient underwent a blood transfusion. 57 Given ribavirin's relatively poor tolerability in patients with chronic kidney disease, and the relatively high SVR rates without ribavirin in patients with normal renal function, even those patients with GT1a, 15, 16, 30, 58, 59 the role of ribavirin for GT1a-infected patients with chronic kidney disease is currently being evaluated in the ongoing RUBY-II study.
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The large C-SURFER study demonstrated that the DAA combination of elbasvir/grazoprevir without ribavirin was well tolerated and achieved an SVR rate of 94% in HCV GT1-infected patients with chronic kidney disease. 61 These data suggest that ribavirin is not needed with elbasvir/grazoprevir to optimize efficacy in HCV GT1a-infected patients with severe renal impairment. The reason for the apparent capacity to omit ribavirin in GT1a-infected patients with renal failure but not, as in C-EDGE, patients with normal renal function (in whom baseline RASs had an adverse impact) 59, 61 is unclear but may be related to the lower baseline HCV RNA levels seen in patients with advanced renal disease, somewhat mitigating the effect of baseline RASs in this population. Additional data focusing specifically on GT1a patients with renal failure and baseline RASs would be useful to definitively evaluate whether ribavirin is entirely dispensable in regimens lacking a nucleotide polymerase inhibitor in this setting.
| Human immunodeficiency virus/HCV coinfection
In patients co-infected with human immunodeficiency virus (HIV)/ HCV, there is a general lack of head-to-head comparative data with and without ribavirin, and most ongoing clinical trials are currently evaluating ribavirin-free therapy. [62] [63] [64] [65] Although the reluctance to use ribavirin in co-infected patients may stem from concerns about additive drug toxicity with antiretroviral therapy, results in co-infected patients have been shown to be generally similar to those seen with HCV mono-infection, suggesting that ribavirin should play a similar clinical role in both populations. International guidelines recommend that HIV/HCV co-infected persons be treated and retreated the same as HCV-infected persons without HIV infection. 22, 23 Therefore, the addition of ribavirin may also be considered to maximize efficacy rates in specific subgroups of patients with HIV/HCV co-infection.
| Optimizing therapy in patients infected with HCV genotypes other than GT1
Results from clinical trials until now have shown that ribavirin confers benefit in select patients with HCV GT1. To date, many of the same insights into ribavirin's role seen with HCV GT1 have been seen in those with other genotypes.
| Genotype 2 or 3
Several phase 2 studies have provided insights into the importance of 
GT3
. 67 Although SVR rates were numerically higher in those who received ribavirin (100%) than in those who did not (93%), with only 14 patients per arm, it is difficult to evaluate the true value of ribavirin in this population. 67 The phase 3 ALLY-3 and ALLY-3+ trials in HCV GT3-infected patients evaluated daclatasvir and sofosbuvir for 12 weeks without ribavirin and for 12 or 16 weeks with ribavirin, respectively. Among patients with cirrhosis, numerically higher SVR rates were achieved in ALLY3+ with both the 12-and the 16-week regimens of daclatasvir and sofosbuvir plus ribavirin (83% [15/18] and 89% [16/18] , respectively) vs the 12-week regimen without ribavirin (65% [22/34] ) in ALLY-3. 68 Further analysis showed that the effect of ribavirin on SVR rates was related to overcoming the impact of baseline RASs. However, an interim analysis evaluating the efficacy of daclatasvir and sofosbuvir with and without ribavirin in clinical practice has shown that very high SVR rates are achieved without ribavirin, including in patients with GT3 infection and compensated cirrhosis, and the addition of ribavirin does not confer additional benefit. 69 Furthermore, it appears that most ongoing trials investigating second-wave DAA combinations, such as the ASTRAL and SURVEYOR studies evaluating the efficacy and safety of sofosbuvir/velpatasvir and ABT-493 (NS3/4A protease inhibitor) plus ABT-530 (NS5A inhibitor), respectively, in patients with HCV GT2 and GT3 infection are doing so without the use of ribavirin.
70-72
Patients with HCV GT2 and GT3 infection were treated with sofosbuvir/velpatasvir for 12 weeks in the ASTRAL-2 and ASTRAL-3 studies, respectively. 70 Although the effect of ribavirin was not assessed in these studies, high SVR rates were achieved in HCV GT2-infected patients (99%; 133/134); however, relatively low SVR rates were observed in specific patient populations in the ASTRAL-3 study.
Overall, 95% (264/277) of HCV GT3-infected patients achieved an SVR, with treatment-experienced patients with and without cirrhosis achieving numerically lower SVR rates of 89% (33/37) and 91%
(31/34), respectively. 70 In a pooled analysis of the ASTRAL studies that included GT3-infected patients in ASTRAL-3, the SVR rate in patients with GT3 infection was numerically lower in those with base- 
| Genotype 4
A small number of HCV GT4-infected patients were included in the phase 3 studies of elbasvir/grazoprevir, C-EDGE 59 and C-SCAPE.
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Initial observations suggest that ribavirin may confer benefit by maximizing SVR rates. C-EDGE enrolled treatment-experienced patients with and without cirrhosis, and irrespective of treatment duration, SVR rates were higher for patients treated with elbasvir/ grazoprevir plus ribavirin compared with the same regimen without ribavirin (12 weeks, 93% [14/15] vs 78% [7/9] ; 16 weeks, 100% [8/8] vs 60% [3/5] respectively). 59 Twenty further treatment-naive HCV GT4 patients without cirrhosis were enrolled in C-SCAPE, and treatment with elbasvir/grazoprevir plus ribavirin yielded similar SVR rates (100%, 10/10) compared with those treated without ribavirin (90%, 9/10). 74 Larger studies are needed to confirm ribavirin's role in reducing virological failure in HCV GT4-infected patients with elbasvir/grazoprevir and to evaluate whether specific patient subgroups are likely to require ribavirin (e.g. those with NS5A baseline resistance).
Combination therapy with ombitasvir/paritaprevir/ritonavir also benefits from the addition of ribavirin in patients with HCV GT4. 75 In the PEARL-I study, following treatment with 12 weeks of ombitasvir/ paritaprevir/ritonavir, 91% (40/44) of treatment-naive non-cirrhotic patients achieved an SVR compared with 100% (42/42) in those treated with the addition of ribavirin. 75 These data suggest that ribavirin may reduce virological failure rates in HCV GT4-infected patients.
Interestingly, all three patients who experienced virological failure were infected with subtype 4d and all had RASs present at the time of virological failure. 75 Adding ribavirin to ombitasvir/paritaprevir/ ritonavir may act in preventing the emergence of RASs and removes HCV GT4 subtype-specific responses to therapy. Furthermore, 100%
(49/49) of treatment-experienced, non-cirrhotic patients achieved an SVR with 12 weeks of ombitasvir/paritaprevir/ritonavir plus ribavirin, leading to the recent approval of this regimen for HCV GT4; a ribavirin-free regimen was not explored.
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A recent study evaluating the efficacy and safety of ledipasvir/ sofosbuvir for 12 weeks in treatment-naive and -experienced HCV GT4-infected patients with and without cirrhosis reported SVR rates of 93%. 76 The role of ribavirin was not evaluated. which it is co-administered. Thus, the AE profile of ribavirin warrants a full re-evaluation in the absence of interferon.
Interferon/peginterferon and ribavirin regimens for chronic HCV had poor tolerability profiles, with relatively high treatment discontinuation rates and declines in haemoglobin to <10 g/dL (Table 2) .
The introduction of first-generation DAAs, boceprevir and telaprevir, to peginterferon plus ribavirin regimens boosted SVR rates, but was associated with even worse tolerability profiles. [3] [4] [5] [6] [7] Current interferonfree DAA regimens are relatively well-tolerated, and while adding ribavirin to these DAA regimens is generally associated with a slightly higher rate of some AEs than ribavirin-free regimens, 15, 16, 30, 31, 78 this does not appear to affect patients' ability to complete treatment.
With the interferon-free, all-oral DAA regimens, discontinuation rates because of AEs are typically below 3%, both with and without ribavirin (Table 2) . 15, 16, 30, 31, 67, 78 AEs (e.g. fatigue, headache, nausea, cough, rash, dyspepsia, insomnia and dyspnoea; Fig. 1C , D) and serious AEs (Table 2) generally occur much less frequently with interferon-free DAA regimens 15, 16, 30, 31, 67, 78 vs combined interferon/peginterferon and ribavirin regimens 1,2 and boceprevir-and telaprevir-based regimens with peginterferon.
3-7
As with interferon-containing regimens plus ribavirin, the most common haematological AE in patients who received the newer DAAs plus ribavirin was anaemia. However, both the frequency and clinical severity of anaemia is greatly reduced compared with that observed in the interferon era, and also the frequency of anaemia appears to vary based on the DAA regimen ( DCV, daclatasvir; DSV, dasabuvir; EBR, elbasvir; GT, genotype; GZR, grazoprevir; HCV, hepatitis C virus; IFN, interferon; LDV, ledipasvir; NR, not reported; OBV, ombitasvir; PegIFN, pegylated interferon; PI, protease inhibitor; PTV, paritaprevir; r, ritonavir; RBV, ribavirin; SAE, serious adverse event; SOF, sofosbuvir; wks, weeks.
SVR. Ribavirin also allows for shortening of therapy, particularly in patients with cirrhosis, without sacrificing efficacy. However, most data in support of a role for ribavirin in the all-oral DAA era are from small studies or subgroups that lack statistical significance.
Ribavirin is relatively well tolerated as part of all-oral DAA regimens and the frequency and severity of anaemia is considerably reduced and easy to manage in the absence of interferon. While ribavirin's mechanism(s) of action remain elusive, it has proven harder to replace than expected and, for the time being, continues to play a useful role in HCV therapy.
